Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the National Agency for the Safety of Medicines and Health Products (ANSM) remain mobilised to allow patients the earliest possible access. possible for innovative treatments of COVID-19.
In addition to vaccination, the most effective lever to avoid severe forms, drug treatments are now validated to provide a complementary solution to the most vulnerable people.
Following the opinion of the ANSM, the HAS authorises early access to the Paxlovid treatment (nirmatrelvir/ritonavir) from the Pfizer laboratory for adults with COVID-19 not requiring oxygen therapy and at high risk of progression to a severe form of the disease.
